Health Organization warns against 'false' medicine used to treat obesity

The World Health Organization has issued a warning about forged medical products used to treat diabetes and weight loss, such as the false semaglutide. The UN Organization monitored 3 forged groups of Ozimbek product (Simaglotide) that were discovered in October 2023 in Brazil, the United Kingdom and Northern Ireland, and in the United States in December 2023. management. This drug belongs to the category of medicine known as the GLP-1-Peptide-1 peptide stimuli (GLP-1), which simulates the work of the natural hormone GLP-1 by stimulating insulin secretion, impeding the release of the glucagon and slows down the emptying of the stomach. The uses of simaglotide and ozimbek help regulate blood sugar levels and increase the feeling of fullness, thereby reducing the total calories. It is also given once a week as an injection, as it has shown a major effectiveness in clinical trials, which significantly improved the control of blood sugar and weight loss in many patients. Ozimbeck has been approved by organizational bodies such as the US Food and Drug Administration, and the European Pharmaceutical Agency, and has become a valuable tool in managing type 2 diabetes and loss in weight loss, which contributes to improving the overall health results of patients. According to a statement from the World Health Organization, the World Wide Monitoring and Monitoring System of the UN Organization has noted an increase in reports related to the adulterous simajlotide products in all geographical areas since 2022. Simaglotide medicine, including the forged brand product, for people with type 2 diabetes to reduce their blood sugar levels. Simaglotide also reduces the risk of cardiovascular disease. Most of the simaglotide products should be jailed weekly, but it is also available in the form of tablets taken orally daily. It has been proven that this medication works to release appetite, in addition to reducing blood sugar levels, and is therefore increasingly prescribed for weight loss in some countries. The World Health Organization took note of the increase in demand for this medicine, as well as reports on their forgery. Planned effects of health and forged products can have harmful effects on humans if it does not contain the necessary raw ingredients as it can lead to health complications caused by the lack of control of glucose levels in the blood or weight. In other cases, there may be another active ingredient that is not announced in the injection system, for example insulin, leading to an unpredictable group of health risks or complications. The drug is not part of the treatments that the World Health Organization recommends to manage diabetes due to its high cost. The UN Organization says that the cost -barrier does not make these products suitable for the public health approach, which aims to ensure access to medicine as widely as possible at the population level, and achieve a balance between the best level of care and which is possible on a large scale in terms of resources. The health organization says there are more affordable treatments available for diabetes, with effects similar to simajlotide on blood sugar and cardiovascular risk. The international organization advises patients who use these products to take precautions, such as buying medicine with prescriptions from licensed doctors, and to buy medicine from unknown or not -verified sources, such as those that can be found online. Global Health says that people should always check the medicine packages and their expiry dates when buying them, and the products as described, and point out that patients in the event of symptomed medicine that can be injected should ensure that they are stored in the fridge.